Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion, plus royalties. Rznomics will lead early-stage research; Lilly to handle development and sales. Don’t miss this list of 3 ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient weight?loss pills. Investors will watch upcoming trial readouts and regulatory ...

Year-to-date, both Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) delivered negative stock performance, at -26.5% and -6.7%, respectively. In recent years, these pharma giants have become even ...

Eli Lilly (NYSE:LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter half of 2024 and has been underperforming since. The latest executive ...

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.

Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America. Happy to have Lilly here on this final day of the conference. We have Lucas Montarce, who's ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/16/25, Eli Lilly (Symbol: LLY), Cencora Inc (Symbol: COR), and Royalty Pharma plc (Symbol: RPRX) will all trade ex-dividend for ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks on Jim Cramer’s radar recently. On Monday’s episode of Mad Money, Jim Cramer ...

Eli Lilly and Company and Purdue University announced a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next ...